Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | CPT1A | P50416 | 1/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030442 | 0.90 | ITGB3 (0.47) | F2F10PLAUPLATITGB3 | |
| SCHEMBL7032391 | 0.89 | ITGB3 (0.43) | F2F10PLAUPLATITGB1 | |
| SCHEMBL7032861 | 0.89 | ITGB3 (0.44) | F2F10PLAUPLATITGB3 | |
| SCHEMBL7035668 | 0.88 | ITGB3 (0.43) | F2F10PLAUPLATITGB3 | |
| SCHEMBL7030474 | 0.88 | F10 (0.43) | F2F10PLAUPLATITGB1 | |
| SCHEMBL7037933 | 0.87 | ITGB3 (0.46) | F2F10PLAUPLATITGB3 | |
| SCHEMBL7251419 | 0.86 | MEN1 (0.42) | F2F10PLAUPLATITGB1 | |
| SCHEMBL7255333 | 0.86 | F10 (0.40) | F2F10PLAUPLATITGB1 | |
| SCHEMBL7030855 | 0.85 | KMT2A (0.46) | F10ITGB1ITGB3APPITGA5 | |
| SCHEMBL7038291 | 0.85 | ITGB3 (0.41) | F2F10PLAUPLATITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | claimed |
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | ASGR1, TEK, APLNR | FOLH1 1773/4885NAAA 997/4885CPT2 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.